Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747540 | 1.00 | L3MBTL1 (0.47) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL22659959 | 0.86 | L3MBTL1 (0.47) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL4959971 | 0.82 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL28177022 | 0.82 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL22710167 | 0.82 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL7149877 | 0.82 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL5514021 | 0.82 | L3MBTL1 (0.53) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL4296816 | 0.80 | L3MBTL1 (0.45) | L3MBTL1MAPTTYRGAAPOLB | |
| SCHEMBL1747537 | 0.79 | MAPK1 (0.42) | L3MBTL1 | |
| SCHEMBL23481289 | 0.77 | L3MBTL1 (0.51) | L3MBTL1MAPTTYRGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100247578-A1 | CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF | SALAMA ZOSER B | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247578-A1 | CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF | EXOSC5, EXOSC9, SSB | L3MBTL1 3820/4885MAPT 1855/4885TYR 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.